Chimeric Therapeutics is a pioneering clinical-stage cell therapy company focused on revolutionizing cancer treatment through innovative immunotherapies. As an Australian leader in the field, the company is dedicated to developing cutting-edge CAR T and NK cell therapies that have the potential to transform patient outcomes in oncology. Their approach goes beyond traditional cancer drug development, aiming to create truly curative therapies for patients with advanced cancer.
The company’s diverse portfolio features three primary assets currently in Phase 1/1b clinical trials: CDH17 CAR T (a first-in-class therapy developed at Penn’s renowned cell therapy center), CLTX (nicknamed ‘The Scorpion Killer’ for its unique use of chlorotoxin derived from scorpion venom), and CORE NK (a potentially best-in-class NK cell platform). Each of these therapies represents a unique approach to targeting and treating different types of cancer, showcasing Chimeric’s commitment to innovative and diverse therapeutic strategies.
Chimeric Therapeutics operates on a strategic model of discovery, development, and commercialization, bringing together a world-class team of cell therapy experts and pioneers. Their mission is to identify the most promising cell therapies with curative potential, drive innovative drug development through agile asset optimization and creative trial designs, and ultimately enable rapid commercialization of breakthrough treatments. By focusing on transformative cell therapies, the company aims to provide hope and more effective treatment options for patients facing advanced cancer.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
